Stay up to date with JL-112's latest developments, milestones, and industry insights.
Content type
Topic
JL-112 preparing public ownership offering for accredited and non accredited shareholders via SEC Regulation D (Rule 506C) and Regulation A+
How our formulation science targets absorption, stability, and outcomes for women navigating menopause—and why early development data matters for the path ahead.
Regulatory strategy and commercial readiness are not afterthoughts—they are built into the company from day one. Here is how we are expanding capability as our pipeline advances.
More than 450 million women face perimenopausal or postmenopausal symptoms globally. The gap is not only medical—it is structural. This piece outlines why JL-112 sees investable opportunity in doing better.
The company has received positive feedback on its regulatory strategy for its lead product candidate targeting hormone replacement, marking an important milestone in the development process.
A new women's health innovation company launches with a mission to transform scientific discoveries into meaningful therapies, led by a team of experienced pharmaceutical and medical professionals.
For news inquiries, partnerships, or interviews, reach out to the JL-112 communications team.